Research programme: anti-CD160 monoclonal antibodies- Alderaan Biotechnology
Latest Information Update: 28 Feb 2024
At a glance
- Originator Alderaan Biotechnology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD160 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer